EP4153167A4 - Method of treating aml subtypes using arginine-depleting agents - Google Patents

Method of treating aml subtypes using arginine-depleting agents Download PDF

Info

Publication number
EP4153167A4
EP4153167A4 EP20943510.6A EP20943510A EP4153167A4 EP 4153167 A4 EP4153167 A4 EP 4153167A4 EP 20943510 A EP20943510 A EP 20943510A EP 4153167 A4 EP4153167 A4 EP 4153167A4
Authority
EP
European Patent Office
Prior art keywords
arginine
depleting agents
treating aml
aml subtypes
subtypes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20943510.6A
Other languages
German (de)
French (fr)
Other versions
EP4153167A1 (en
Inventor
Sui Yi Kwok
Norman Fung Man Wai
Terence Shau Yin WAI
Yun Chung Leung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vision Global Holdings Ltd
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of EP4153167A1 publication Critical patent/EP4153167A1/en
Publication of EP4153167A4 publication Critical patent/EP4153167A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20943510.6A 2020-06-29 2020-06-29 Method of treating aml subtypes using arginine-depleting agents Pending EP4153167A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/098681 WO2022000151A1 (en) 2020-06-29 2020-06-29 Method of treating aml subtypes using arginine-depleting agents

Publications (2)

Publication Number Publication Date
EP4153167A1 EP4153167A1 (en) 2023-03-29
EP4153167A4 true EP4153167A4 (en) 2024-02-28

Family

ID=79317763

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20943510.6A Pending EP4153167A4 (en) 2020-06-29 2020-06-29 Method of treating aml subtypes using arginine-depleting agents

Country Status (6)

Country Link
EP (1) EP4153167A4 (en)
KR (1) KR20230104110A (en)
CN (1) CN115697320A (en)
CA (1) CA3187578A1 (en)
TW (1) TW202206095A (en)
WO (1) WO2022000151A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4069280A4 (en) * 2019-12-02 2024-01-03 The Hong Kong Polytechnic University Methods for inducing intermittent fasting and modulating autophagy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015512A1 (en) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. A modified arginine deiminase
WO2013151568A1 (en) * 2012-04-04 2013-10-10 Polaris Group Methods of treatment with arginine deiminase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180010114A1 (en) * 2016-07-05 2018-01-11 Polaris Group Combination cancer immunotherapies with arginine depletion agents
EP3515495A4 (en) * 2016-09-26 2020-08-26 Ensemble Group Holdings Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006015512A1 (en) * 2004-08-11 2006-02-16 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. A modified arginine deiminase
WO2013151568A1 (en) * 2012-04-04 2013-10-10 Polaris Group Methods of treatment with arginine deiminase

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHOW JEREMY P. H. ET AL: "A modified arginine-depleting enzyme NEI-01 inhibits growth of pancreatic cancer cells", PLOS ONE, vol. 15, no. 4, 30 April 2020 (2020-04-30), US, pages e0231633, XP093119859, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0231633 *
DATABASE Geneseq [online] 15 June 2007 (2007-06-15), "Arginine deiminase.", retrieved from EBI accession no. GSP:AEF74467 Database accession no. AEF74467 *
DATTA SAYANTAP ET AL: "Human Arginase I (Arg I)-A Potential Broad-spectrum Anti-cancer Agent: Perspectives and the Road Ahead", RESEARCH & REVIEWS: JOURNAL OF ONCOLOGY AND HEMATOLOGY, vol. 9, no. 3, 1 January 2020 (2020-01-01), pages 23 - 35, XP055972770, DOI: 10.37591/rrjooh.v9i3.2312 *
See also references of WO2022000151A1 *
TSAI HUI-JEN ET AL: "A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients", SCIENTIFIC REPORTS, vol. 7, no. 1, 12 September 2017 (2017-09-12), US, pages 1 - 10, XP055886883, ISSN: 2045-2322, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-017-10542-4.pdf> DOI: 10.1038/s41598-017-10542-4 *

Also Published As

Publication number Publication date
WO2022000151A1 (en) 2022-01-06
CN115697320A (en) 2023-02-03
TW202206095A (en) 2022-02-16
EP4153167A1 (en) 2023-03-29
CA3187578A1 (en) 2022-01-06
KR20230104110A (en) 2023-07-07

Similar Documents

Publication Publication Date Title
EP4061349A4 (en) Methods of treating coronavirus
EP4117728A4 (en) Method for treatment of covid-19-associated conditions
EP4181925A4 (en) Methods of treating proteinopathies
EP4153167A4 (en) Method of treating aml subtypes using arginine-depleting agents
EP3976042A4 (en) Methods of treating cholangiocarcinoma
AU2022233762A1 (en) Method of treating diseases using gremlin1 antagonists
EP3775074A4 (en) Compositions and methods for treating a substrate and for improving adhesion of an image to a treated substrate
EP4143202A4 (en) Method of treating ship1-mediated diseases using pelorol derivatives
EP4132503A4 (en) Methods for treatment of coronavirus infections
EP4132535A4 (en) Compositions and methods for the treatment of infection-induced cardiomyopathy
EP3969623A4 (en) Methods of treating cancer using chk1 inhibitors
EP4103200A4 (en) Method of treatment using meta-arsenite
AU2021902405A0 (en) Method of treatment
AU2021900204A0 (en) Method of treatment
AU2020900433A0 (en) Method of treatment
AU2020900220A0 (en) Method of Treatment
AU2022903002A0 (en) Method of Treating
EP4121049A4 (en) Methods of treating lymphedema with deupirfenidone
AU2021903030A0 (en) Methods of treatment
AU2021902512A0 (en) Methods of treatment
AU2023903893A0 (en) Method of treatment
AU2023902382A0 (en) Methods of treatment
AU2023901658A0 (en) Method of Treatment
AU2023901529A0 (en) Method of Treatment
AU2023901341A0 (en) Method of Treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082514

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240129

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/765 20060101ALI20240123BHEP

Ipc: C07K 14/00 20060101ALI20240123BHEP

Ipc: A61K 31/335 20060101AFI20240123BHEP